Walgreens is wading into the self-pay GLP-1 space, going head-to-head with telehealth subscription offerings. | Walgreens is wading into the self-pay GLP-1 space, going head-to-head with telehealth ...

The program connects self-pay patients with clinicians to access GLP-1s, including Wegovy, starting at $149 per month, with no subscription fee.

Retatrutide helped trial participants lose up to 28.7% of their body weight, but experts warn about excessive weight loss.

Walgreens has expanded its virtual care platform to include weight management services, offering $49 clinician-guided visits for eligible adults using GLP-1 therapies. The new Walgreens Weight ...

Walgreens is launching Walgreens Weight Management, a new digital health care offering designed to help eligible adults ...

A whopping 85% of men experience significantly thinning hair by age 50, and two-thirds experience noticeable hair loss by age ...

Medications such as Wegovy and Zepbound will no longer be covered for weight loss, although GLP-1 drugs for diabetes will still be approved.

Eli Lilly (LLY) has built up its inventory for its experimental weight loss pill, orforglipron, as the Indiana-based pharma giant awaits a potential FDA approval for the oral GLP-1 drug over the ...

Eli Lilly and Company (NYSE: LLY) has stockpiled $1.5 billion worth of inventory of its experimental oral weight-loss drug, orforglipron, according to a regulatory filing on Thursday. This significant ...

Novo Nordisk stock surged after Hims & Hers scrapped plans to sell a copycat version of the drugmaker’s weight-loss pill following pressure from U.S. regulators. Shares in Novo Nordisk jumped nearly 7 ...

Novo Nordisk said it filed a federal lawsuit Feb. 9 against telehealth provider Hims & Hers, alleging the company infringed on Novo's patent by selling versions of its blockbuster weight-loss drug ...